ArticlePloS one2018
Twenty-seven years of screening for Shiga toxin-producing Escherichia coli in a university hospital. Brussels, Belgium, 1987-2014.
Article in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 48 citations in OpenAlex.
- Factors Governing the Cross-Species Virulence of Shiga Toxin-ProducingPathogens (Basel, Switzerland) · 2026Article
- Sheep-associated Escherichia coli in Albania show high genomic similarity to European ovine lineages and a conserved core resistome.FEMS microbiology letters · 2026Article
- Genomic epidemiology reveals statewide dispersal of clinical Shiga toxin-producingMicrobiology spectrum · 2026Article
- Isolation and characterization of bacteriophages from clinical enterohemorrhagicMicrobiology spectrum · 2025Article
- Emerging hybrid shigatoxigenic and enteropathogenicClinical microbiology reviews · 2025Review
- Isolation and Detection of the Emerging PathogenMicroorganisms · 2024Article
- Intestinal Carriage of Two DistinctPathogens (Basel, Switzerland) · 2024Article
- Characterization of Escherichia coli strains producing Shiga Toxin 2f subtype from domestic Pigeon.Scientific reports · 2024Article
- A Comprehensive Review on Shiga Toxin Subtypes and Their Niche-Related Distribution Characteristics in Shiga-Toxin-ProducingMicroorganisms · 2024Review
- Shiga Toxin‒Producing Escherichia coli Diagnoses from Health Practitioners, Queensland, Australia.Emerging infectious diseases · 2024Review
- The diverse landscape of AB5-type toxins.Engineering microbiology · 2023Review
- Article
- Transforming Shiga toxin-producingFrontiers in microbiology · 2023Article
- Identification of Five Serotypes of EnteropathogenicVeterinary sciences · 2022Article
- Microbiology and Epidemiology ofMicroorganisms · 2022Review
- Characterization of Atypical Shiga Toxin Gene Sequences and Description of Stx2j, a New Subtype.Journal of clinical microbiology · 2022Article
- Molecular Detection of Non-O157 Shiga Toxin-ProducingMicroorganisms · 2022Article
- ABToxins · 2022Review
- Therapeutic Antibodies Against Shiga Toxins: Trends and Perspectives.Frontiers in cellular and infection microbiology · 2022Review
- Prevalence and Whole-Genome Sequence-Based Analysis of Shiga Toxin-Producing Escherichia coli Isolates from the Recto-Anal Junction of Slaughter-Age Irish Sheep.Applied and environmental microbiology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveSince 1987 all fecal samples referred to the clinical microbiology laboratory of the UZ Brussel were screened for the presence of Shiga toxin-producing E. coli (STEC). In this study all STEC strains isolated over a period of 27 years (1987-2014) were reexamined to achieve deeper insight in the STEC infections in our patient population.
methodsA total of 606 STEC strains from 604 patients were subjected to molecular methods for shiga toxin (stx) subtyping, detection of additional virulence genes, typing of the O-serogroups, and phylogenetic relatedness assessment of STEC O157:H7/H-.
resultsSince the introduction of PCR in 1991 the annual positivity rates varied between 1.1% and 2.7%. The isolation rate of STEC O157:H7/H- remained stable over the years while the isolation rate of non-O157 serotypes increased, mainly since 2011. The majority of the patients were children. Uncomplicated- and bloody diarrhea were the most prevalent gastrointestinal manifestations (respectively 51.9% and 13.6%), 4.3% of the strains were related to the hemolytic uremic syndrome (HUS), and 30.2% of the patients showed none of these symptoms. The strains were very diverse; they belonged to 72 different O-serovars and all stx subtypes except stx1d and stx2g were identified. Out of the 23 stx2f-positives one was associated with HUS and one belonged to the E. albertii species. As seen in other studies, the frequency of strains of the O157:H7/H- serotype and strains carrying stx2a, eaeA and ehxA was higher in patients with HUS.
conclusionsThe characteristics and trends of STEC infection seen in our patient population are similar to those noted in other countries. STEC infections in our hospital are mainly sporadic, and a substantial portion of the patients were asymptomatic carriers. Human STEC Stx2f infection was less rare than previously assumed and we report the first Belgian STEC stx2f HUS case and stx2f positive E. albertii infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.